Background. The relevance of viral infections in the development of allograft lesions is still unclear, although some viruses have been implicated. The present study investigated systemic and intrarenal viral infections in kidney transplant recipients and their association with the risk of acute rejection and chronic allograft injuries that are predictive of long-term dysfunction.
follow-up of at least 2 years, and (3) whose follow-up allograft biopsy specimens, obtained during month 6 after transplantation, were adequate for histological analysis according to the Banff criteria. According to these inclusion criteria, 69 patients were selected, including 28 female patients (median age, 12.5 years; range, 2-26 years) and 41 male patients (median age, 14 years; range, 2-27 years); 13 patients were Ͻ6 years old, 4 received transplants from living relatives, and 65 received transplants from deceased donors. Fifteen donors were Ͻ6 years old (median age, 12 years; range, 1-45 years).
Patients were treated with an immunosuppressive regimen, including basiliximab induction, tapered dose of prednisone, cyclosporin A (24 patients) or tacrolimus (45 patients), and mofetil mycophenolate. Steroids were washed out after 6 months if there was no evidence of clinical or subclinical acute rejection [7, 8] . Acute clinical and subclinical rejection corresponding to category 4 in the Banff 2005 classification (acute T cell-mediated rejection) was treated with pulse III methylprednisolone (500 mg/m 2 /dose). No cases of steroidresistant acute cellular rejection or acute humoral rejection were observed. Hypertensive patients were treated with appropriate antihypertensive therapy. All patients received anti-human cytomegalovirus (HCMV) prophylaxis for 6 months, except for recipients who were serologically negative for HCMV and whose donors were negative [8] . Patients who were serologically negative for varicella zoster virus (VZV) were vaccinated against VZV before transplantation. Patients were monitored for viral infections via viral DNAemia and/or serological assays performed the day of transplantation (baseline) and at scheduled times after transplantation: weekly until day 30, every 2 weeks until month 3, monthly until month 12, and every 3 months until month 24 . Viral DNAemia was always tested in patients with clinical signs and symptoms. Viral infections, whether symptomatic or asymptomatic, were treated as reported elsewhere [8] .
Follow-up allograft biopsies were performed at 6, 12, and 24 months in patients with stable renal function for at least 2 months before the biopsy and in the absence of clinical contraindications (e.g., coagulation disorders, hypertension, and anatomic anomalies). All 69 patients underwent biopsy at 6 months; 64 and 45 patients also underwent biopsy at 12 and 24 months, respectively. Baseline biopsy specimens obtained at bench surgery before kidney implantation were available for 57 patients. In addition to follow-up biopsies, 9 patients also underwent diagnostic biopsies for episodes of acute allograft dysfunction at a median of 2 months after transplantation (range, 1-22 months). Written informed consent was obtained from the patients or their parents, and the study was performed according to Declaration of Helsinki guidelines with the approval of the local ethics committee.
Histological analysis. Renal biopsies were performed with ultrasound guidance, using a 1.2-mm needle. Two tissue samples were obtained for paraffin embedding and freezing. All biopsy specimens were blindly reanalyzed by L.M. according to the Banff classification (first described in 1997 and updated in 2005) [1, 2] . For the purpose of the study and statistical evaluation, the specimens were classified as reported in table 1.
Detection of viral nucleic acids in allograft biopsy specimens. All biopsy specimens were screened by quantitative real-time polymerase chain reaction (PCR) for the presence of herpes simplex virus (HSV)-1, HSV-2, VZV, HCMV, human herpesvirus (HHV)-6, HHV-7, Epstein-Barr virus (EBV), HHV-8, polyomaviruses BK virus (BKV) and JC virus (JCV), and B19 DNA. Total DNA was purified from frozen tissue sections by means of the QIAamp DNA Mini Kit (Qiagen). Approximately 100 ng of total DNA was used for quantitative real-time PCR with the oligonucleotide primers and TaqMan probes reported elsewhere and listed in table 2 [9 -13] . The number of cells present in each sample was estimated by amplification of the ␤-globin gene [9] . The detection limit of real-time PCR methods was 0.01 copies/1000 cells and was determined by serial dilutions of a plasmid containing the PCR fragment in a sample negative for the presence of viruses.
Virological data. We reviewed clinical data on symptomatic and asymptomatic viral infections defined by the presence of viral DNAemia and/or seroconversion. EBV, HCMV, BKV, and B19 DNAemia were measured by quantitative real-time PCR of blood samples, as described elsewhere [9 -11] . IgM and IgG antibody testing for HCMV infection was performed by ELISA, using a commercially available kit (Enzygnost; Dade Behring). Testing for IgM antibodies against EBV-viral capsid antigen NOTE. An adequacy threshold of 7 glomeruli and 1 artery was considered an inclusion criterion. (VCA) and IgG antibodies against EBV-early antigen, EBV-VCA, and EBV-Epstein-Barr nuclear antigen was performed by ELISA (DiaSorin). B19 IgM and IgG were detected by enzyme immunoaassay (Biotrin). Serological data and DNAemia results for HHV-6, HHV-7, HHV-8, and JCV were not analyzed in this study, because they were not available for all patients and for all time points in the follow-up period.
Renal function tests. We retrospectively analyzed creatinine clearance, calculated according to Swartz's formula, and proteinuria, expressed as grams per liter; these values were measured when allograft biopsy specimens were obtained.
Statistical analysis. Data are expressed as means Ϯ SDs or as medians and ranges. Continuous variables with a normal distribution were analyzed by Student's t test, and those with a nonnormal distribution were analyzed by Wilcoxon rank sum test. Categorical variables were analyzed by 2 test. The cumulative risk of viral infections or development of allograft lesions was estimated by the Kaplan-Meier method, and groups were compared by log-rank test. Univariate and multivariate Cox proportional hazards models were used to analyze variables associated with the risk of allograft lesions. All comparisons were 2-sided, and differences were considered statistically significant at P Ͻ .05.
RESULTS

Viral
DNA detection in donor kidneys. Baseline allograft biopsy specimens provided information on the prevalence of viral genomic sequences in the kidneys of healthy young subjects as well as on the source of viral infection in the recipient. Overall, viral DNA was detected in 46% of baseline biopsy specimens, with coinfections in half of the cases. The prevalence of B19 and HHV-6 DNA, which often presented as a coinfection, was relatively high, whereas other viruses were either rarely detected or absent (table 3) . Viral DNA was more frequently detected in the kidneys from donors Ͼ6 years of age than in younger donors (56% vs. 9%; P Ͻ .05). All baseline biopsy specimens appeared histologically normal, except for 1 with fibrointimal thickening of a small artery and 3 with mild interstitial fibrosis.
Intrarenal viral detection, allograft lesions, and renal function during follow-up. In follow-up allograft biopsy specimens, the overall prevalence of viral DNA was ϳ70%, and coinfections were present in 25% of biopsy specimens (table 3) . B19, HHV-6, EBV, and BKV were the most frequently detected viruses. The prevalence and cumulative risk of EBV and BKV increased during follow-up (table 3 and figure 1 ). HCMV, HHV-7, HHV-8, and JCV sequences were detected in a low percentage of cases, whereas HSV-1, HSV-2, and VZV sequences were never detected (table 3) . B19 typing demonstrated B19 type 1 in all but 1 patient, who had B19 type 2 infection.
The median intrarenal genome copy number of BKV, HHV-6, and B19 was ϳ7 copies/1000 cells, ranging from a maximum of 3000 copies/cell for BKV, 25 copies/cell for B19, and 140 copies/cell for HHV-6 to the detection limit of our real-time PCR methods. The EBV DNA load was generally very low (median, 0.2 viral DNA copies/1000 cells; range, 7 copies/1000 cells to the detection limit). Viral load was not significantly associated with the presence and severity of allograft histological lesions. In follow-up protocol biopsy specimens, histological abnormalities were already detectable 6 months after transplantation in 37% of cases. The prevalence and cumulative risk of chronic allograft injury increased with time; ϳ70% of patients showed chronic pathological changes within 24 months of follow-up, but the prevalence of acute rejection decreased during follow-up (table 3 and figure 1A) . Any viral DNA was more frequently detected in kidney biopsy specimens with chronic allograft injury than in those with normal histological findings or acute rejection (79.4% vs. 61.4% vs. 56.6%, respectively), but the differences were not significant. The presence of chronic changes at 24 months was not associated with previous histological or clinical acute rejection or with recipient age, sex, immunosuppressive regimen, or blood pressure. No subclinical acute antibodymediated rejection, chronic obstruction, chronic bacterial pyelonephritis, recurrence of primary disease, or de novo glomerulonephritis was observed in follow-up biopsy specimens.
Histological evaluation of diagnostic biopsy specimens showed 4 cases of T cell-mediated acute rejection (1 with HHV-6 DNA present), 1 case of C4d-positive acute antibodymediated rejection associated with B19 DNA detection, 2 cases of BKV-associated nephropathy, 1 case of thrombotic microangiopathy associated with B19 DNA detection, and 1 specimen with normal histological findings. In the 2 cases of BKVassociated nephropathy, the virus was detected in the diagnostic allograft biopsy for the first time, whereas, in the other viruspositive diagnostic biopsy specimens, viruses had already been present in previous follow-up biopsy specimens. Data regarding diagnostic biopsy specimens were included for statistical analysis.
During follow-up, renal function remained stable in most patients (table 3) . Analysis of matched data on intrarenal viral DNA detection and corresponding renal function tests demonstrated a significant difference only for B19, because patients with B19-positive biopsy specimens had significantly higher proteinuria levels than did those with B19-negative biopsy specimens (0.219 Ϯ 0.352 vs. 0.103 Ϯ 0.166 g/L; P Ͻ .05).
Persistent viral detection in the kidney allograft and risk of allograft lesions. The presence of viral DNA sequences in the allograft was generally persistent during follow-up. This was especially true for B19 and HHV-6, which persisted in the recipient graft in 85% and 71% of cases, respectively, when the donor kidney was positive. Persistent infection, defined as repeated viral DNA detection in at least 2 consecutive allograft biopsy specimens, was also common for viruses involving the graft after transplantation, such as EBV and BKV, which were persistently detected in 71% and 69% of cases of allograft infection, respectively. Two cases of persistent HHV-7 and JCV infection were observed.
Compared with patients without persistent viral detection, those with intrarenal viral persistence had lower (although not significantly so) creatinine clearance (mean, 56.82 Ϯ 20.27 vs.
65.41 Ϯ 17.55 mL/min/1.73 m 2 at 12 months after transplantation; P ϭ .07) and significantly higher proteinuria levels (mean, 0.158 Ϯ 0.238 vs. 0.035 Ϯ 0.052 g/L at 12 months after transplantation; P Ͻ .01). Considering each virus, patients with intrarenal persistent B19 infection had higher proteinuria levels than those with no B19 persistence (0.317 Ϯ 0.342 vs. 0.119 Ϯ 0.09 g/L at 12 months after transplantation; P Ͻ .05).
We hypothesized that viral persistence could be involved in allograft damage, so we investigated the possible association between intrarenal viral DNA persistence and occurrence of acute rejection or chronic injury. Kaplan-Meier analysis and the logrank test showed that persistent viral infection was associated with the development of chronic allograft injury ( 2 ). These results were confirmed by univariate and multivariate Cox proportional hazards regression (table 4). The histological appearance of chronic allograft injury associated with B19 infection was characterized by matrix increase (mm123), often with glomerular sclerosis, tubular atrophy (ct1, ct2), interstitial fibrosis (ci1, ci2), and fibrointimal thickening of arteries (cv1, cv2). The type of immunosuppressive regimen and the treatment of acute clinical and subclinical rejection were not associated with intrarenal viral DNA detection and persistence, histological evidence of kidney damage, or renal function.
Systemic viral infections and intrarenal viral DNA detection. Data on matched intrarenal viral DNA and viral DNAemia were analyzed to assess whether the presence of viral DNA in the allograft was associated with concomitant systemic infection. During follow-up, 34 patients had episodes of asymptomatic EBV DNAemia (including 15 with primary infection and 19 with EBV reactivation), and 3 had symptomatic EBV DNAemia (all primary infections). The presence of EBV DNA in the kidney allograft, demonstrated in 15 patients, was always associated with DNAemia and was more frequently observed during primary EBV infection (11 patients) than during EBV reactivation in seropositive recipients (4 patients). Moreover, the EBV DNA load in the graft showed a trend toward a positive correlation with EBV DNAemia levels (data not shown).
Symptomatic HCMV DNAemia occurred in 2 patients (1 with primary HCMV infection and 1 with HCMV reactivation), and asymptomatic HCMV DNAemia occurred in 14 patients; all episodes occurred within the first 6 months after transplantation. The 2 HCMV DNA-positive biopsy specimens were associated with HCMV DNAemia, whereas all other patients with negative biopsy specimens had negative day-matched findings for HCMV DNAemia. Episodes of BKV DNAemia were demonstrated in 8 patients, including 6 with asymptomatic infections and 2 with very high viral loads and BKV-associated nephropathy, who developed acute renal graft dysfunction at 10 and 15 months after transplantation, respectively. In these 2 patients, who eventually developed chronic allograft injury, BKV DNA was also detected in baseline and follow-up biopsy specimens. In all cases of BKV DNAemia, matched allograft biopsy specimens were positive for BKV DNA, but 30% of patients with BKV DNA-positive biopsy specimens had negative day-matched findings for viremia.
Episodes of B19 DNAemia were demonstrated during primary infection in 9 B19-seronegative patients, 7 of whom had subsequently persistent B19 DNAemia. All these patients had concomitant high copy numbers of B19 DNA in allograft biopsy specimens and histological findings of acute rejection, followed by severe chronic injury. Two of these patients were symptomatic: one experienced an episode of acute renal graft dysfunction with histological evidence of thrombotic microangiopathy, and the other experienced an episode of C4d-positive acute vascular rejection with fever, rash, and hyporegenerative anemia in the first month after transplantation. Retrospective analysis of their baseline and follow-up biopsy specimens demonstrated the presence of B19 DNA in all samples. Five other seronegative recipients of a B19 DNA-positive graft had no DNAemia and remained seronegative during follow-up, although B19 DNA was persistently detected in follow-up kidney biopsy specimens. B19 DNA was also persistently detected in the allografts of seropositive recipients of a B19-positive graft, although these patients did not show B19 DNAemia at follow-up evaluation.
Overall, analysis of matched data on intrarenal viral DNA detection and viral DNAemia indicated that EBV and HCMV detected in the kidney allograft could derive from circulating blood during systemic infection or reactivation but that BKV and B19 seem to target the kidney, where they establish persistent infection.
Univariate and multivariate Cox proportional hazards regression was performed to assess whether episodes of viral DNAemia (both symptomatic and asymptomatic) were risk factors for the occurrence of acute rejection or chronic allograft injury. The results of these analyses showed that the occurrence of HCMV DNAemia was a significant risk factor for the development of acute rejection, whereas episodes of B19 DNAemia occurred more frequently in patients who developed chronic allograft injury, although this association did not reach statistical significance (table 4 and figure 2 ). The occurrence of HCMV and B19 DNAemia generally preceded the appearance of histological signs of acute rejection and chronic allograft injury, respectively.
DISCUSSION
The present study, conducted in young kidney transplant recipients, represents the first investigation of intrarenal and systemic infections with different viruses and their association with the occurrence of allograft injury. It demonstrated that the prevalence of acute and chronic lesions in young transplant recipients is high and is similar to that reported in adult patients [3] . The novelty of the present study is the demonstration that viral DNA, mainly of B19, HHV-6, EBV, and BKV, is detectable in ϳ50% of native kidneys and in 70% of kidney allografts and that intrarenal B19 persistence is associated with the development of chronic allograft injury. Moreover, this study confirms that episodes of HCMV DNAemia are a risk factor for acute rejection.
In our study, B19 DNA was already detectable in one-third of donor kidneys, in agreement with data on the normal kidney [14] , and in most cases it persisted in the kidney allograft after transplantation. In kidney transplant recipients, active B19 infection has been associated with acute and chronic aplastic anemia [15] [16] [17] , allograft dysfunction [18] , collapsing glomeru- lopathy [14, 19] , and thrombotic renal allograft microangiopathy [20] . Here, we report 2 cases of acute renal graft dysfunction associated with thrombotic microangiopathy and antibodymediated rejection due to B19 infection. This study demonstrates that the asymptomatic persistence of B19 DNA in the renal allograft and B19 DNAemia are associated with a higher rate of chronic allograft lesions. The cellular reservoir (endothelial or epithelial) and the mechanism of kidney damage remain to be elucidated [21] . We can hypothesize that kidney injury might be linked to persistent B19 replication in the allograft. In fact, prolonged B19 DNAemia and intrarenal detection of B19 DNA, associated with severe chronic injury, occurred frequently in seronegative recipients of a B19-positive graft. In these patients, immunosuppressive therapy and other noxae may have increased graft susceptibility to B19-induced damage. It is conceivable that prolonged active B19 infection could also cause nephrotoxicity in recipients of different types of transplants and in patients with other pathological conditions. Moreover, persistent active B19 infection could damage other target tissues, as demonstrated in subjects with left ventricular cardiac dysfunction and B19-positive endomyocardial biopsy specimens [22] . In these patients, clearance of viral genome was associated with a significant hemodynamic improvement, whereas B19 persistence led to decreased ventricular function [22] .
Herpesvirus-associated diseases, especially EBV-related posttransplant lymphoproliferative disorder and HCMV disease, represent important complications in renal transplant recipients [6, 23] . The presence of herpesviruses in the renal allograft has to date been investigated only by Sebekova et al. [24] , who demonstrated that detection of HCMV, EBV, HHV-6, and HHV-7 DNA in the renal tissue was associated with chronic allograft injury. Accordingly, in our experience, detection of viruses (any viral DNA) in the allograft was significantly associated with chronic allograft injury, but when we considered each virus individually, the intrarenal detection of herpesviruses did not seem to be significantly associated with allograft lesions, even though some herpesviruses, such as EBV and HHV-6, were quite frequently detected in kidney allografts. In particular, persistent EBV DNA detection was more frequent, although not significantly so, in patients in whom subclinical acute rejection occurred, whereas the presence and persistence of HHV-6 was not associated with increased risk of graft dysfunction or histological lesions. In this regard, reports from the literature are controversial [25] [26] [27] [28] . Intrarenal detection of HCMV DNA was rare, notwithstanding the occurrence of several episodes of symptomatic and asymptomatic DNAemia. We have demonstrated here that episodes of HCMV DNAemia were a risk factor for histological acute rejection, in agreement with findings in the literature [23, 29 -31] . Because HCMV DNA was not detectable in the allograft, the virus probably caused acute rejection through indirect effects on the host immune-inflammatory response [6] . Moreover, it is well known that antirejection treatment predisposes transplant recipients to HCMV disease, even though in our series episodes of HCMV DNAemia generally preceded the appearance of subclinical acute rejection.
Active BKV infection is a well-recognized cause of progressive renal damage, as reported in ϳ5% of renal transplant recipients [32] and also as seen in our 2 patients with BKV-associated nephropathy. Besides these 2 symptomatic cases, BKV DNA was frequently detected in the allografts of asymptomatic patients, where the virus established persistent infection. However, no significant association was demonstrated between intrarenal BKV DNA persistence and allograft histological changes. We cannot exclude the possibility that a longer period of persistent infection could be required to produce allograft injury [32, 33] . Unlike BKV, the polyomavirus JCV, which has also been associated with nephropathy [34] , was rarely detected in our patients.
In conclusion, this comprehensive analysis of intrarenal and systemic viral infections in kidney transplant recipients demonstrates that viral infections are risk factors for renal allograft damage. Besides confirming the association between acute rejection and episodes of HCMV DNAemia (even asymptomatic ones), this study demonstrates for the first time that genome sequences of a number of viruses are detectable in a high proportion of kidney allografts. In most cases, intrarenal infections are persistent and asymptomatic, with the exception of a few acute episodes. Although asymptomatic, persistent intrarenal infections, especially B19 infections, are associated with a risk of allograft lesions that are predictive of long-term renal dysfunction. Thus, investigation and appropriate management of intrarenal viral infections in transplant recipients could improve survival of the kidney allograft.
